93 chemo infusions delivered at home with zero reactions, Mayo Clinic reports

Ninety-three IV chemotherapy infusions. Ten patients. Zero treatment-related infusion reactions. Zero catheter-related infections. That is the headline from a Mayo Clinic pilot study published in NEJM Catalyst, and it may signal the beginning of a significant shift in how cancer care is delivered in the United States.

The numbers are small. But what they represent — chemotherapy administered safely in patients' living rooms rather than hospital infusion centers — challenges a deeply entrenched assumption in oncology: that the toxicity and complexity of IV chemo requires a clinical setting for every single dose.

What the Cancer CARE Beyond Walls model looks like

The program behind this data is called Cancer CARE Beyond Walls (Connected Access and Remote Expertise), developed at Mayo Clinic's Florida campus. It is not simply a matter of sending a nurse to someone's house with a bag of drugs. The model integrates three layers: virtual visits with oncologists, continuous remote patient monitoring, and in-home clinical services provided by a multidisciplinary team.

Each infusion followed the same safety protocols that would apply in a hospital. The difference was the setting. Patients received treatment in their own homes while maintaining a continuous digital connection to their care team. Vital signs were monitored remotely. Any emerging concerns could be addressed in real time.

Roxana Dronca, M.D., site director of the Mayo Clinic Comprehensive Cancer Center in Florida and director of the program, framed it plainly: the model aims to reduce the burden on patients without compromising the standards they expect from a major cancer center.

The burden that nobody talks about enough

Cancer treatment is brutal in ways that extend well beyond the drugs themselves. Patients often spend entire days in infusion centers. For those who live far from treatment facilities — and in the United States, many do — the travel alone can be exhausting and expensive. A round trip of several hours, undertaken while nauseated and immunocompromised, is not just inconvenient. It is a genuine barrier to care.

Then there are the cascading effects. Lost work days. Childcare complications. The emotional toll of spending week after week in a clinical environment that, however well-intentioned, is nobody's idea of a healing space. For elderly patients or those with limited mobility, the logistics of getting to an infusion center can become the hardest part of treatment.

Home-based chemotherapy does not eliminate the side effects of the drugs. But it removes the travel, the waiting rooms, and the disruption to daily life. In the Mayo pilot, most surveyed participants reported high satisfaction with at-home care and said they would recommend the model to others.

Ten patients, not ten thousand

The limitations here are straightforward and the researchers did not shy away from them. This was a pilot study — a feasibility and safety assessment, not a definitive trial. Ten patients is enough to demonstrate that a concept works in practice but far too few to draw broad conclusions about comparative effectiveness, cost savings, or outcomes across diverse patient populations.

The study did not include a control group receiving standard in-center infusions, so there is no direct comparison of outcomes between settings. Patient selection likely skewed toward those considered lower-risk for infusion complications, which is appropriate for a pilot but limits how far the results can be extrapolated.

We also do not know the full cost picture. Home-based care involves sending trained clinicians to individual locations, which could be more expensive per infusion than centralized delivery — or less expensive, once reduced overhead and potential decreases in emergency room visits are factored in. The economics have not been worked out yet.

The randomized trial is already underway

Mayo Clinic launched a randomized clinical trial in August 2023 to address these gaps. The trial compares home-based chemotherapy directly against standard infusion center care, measuring safety, patient experience, clinical outcomes, and costs. It is still enrolling patients.

This is the right next step. Pilot data generates hypotheses; randomized trials test them. If the trial confirms what the pilot suggests — that home chemo is safe, preferred by patients, and at least cost-neutral — the implications for cancer care delivery would be substantial.

The model could be particularly important for expanding access in rural areas, where infusion centers may be hours away. It could also lower barriers to clinical trial participation, a persistent problem in oncology. Many patients who are eligible for trials decline because the logistical demands of frequent clinic visits are too high. Bringing some of those visits to the patient's home could change the calculus.

Not a fit for every patient or every drug

Home-based chemotherapy will not replace infusion centers entirely. Some regimens carry high risks of acute reactions that require immediate clinical intervention. Some patients live in situations where home infusion is impractical — inadequate space, lack of reliable internet for remote monitoring, or absence of a caregiver who can assist if problems arise.

But for the subset of patients receiving well-tolerated regimens who face significant travel or logistical barriers, the Cancer CARE Beyond Walls model offers something that has been missing from oncology for decades: a way to meet patients where they are, literally.

The senior author on the pilot study is Cheryl Willman, M.D., Stephen and Barbara Slaggie Executive Director of Mayo Clinic Cancer Programs. The full results and author disclosures are available in the published paper.